Journal profile · BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY
Human Vaccines & Immunotherapeutics
ISSN 1554-8600 · eISSN 2164-554X · TAYLOR & FRANCIS INC · UNITED STATES · Monthly · Founded 2005
Human Vaccines & Immunotherapeutics: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.13; JCR Q2 (journal website); subscription journal; APC charged, amount not published; median 95 days to acceptance (100 articles, last 24 months); community-reported acceptance: about 50%; 514 articles a year; indexed in SCIE.
Scope
Aims, scope and focus
Human Vaccines & Immunotherapeutics is published by TAYLOR & FRANCIS INC and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Vaccine Coverage and Hesitancy, Influenza Virus Research Studies and Bacterial Infections and Vaccines, together about 28.1% of its articles. Its main subfields are Epidemiology. (generated from OpenAlex topic counts and CAS ranking data)
Human Vaccines & Immunotherapeutics is an open access peer-reviewed journal publishing international research into human vaccinology and immunotherapy, including novel and experimental vaccine and immunotherapeutics exploration. The journal's audience includes clinicians, researchers, medical professionals, epidemiologists, public health workers, biotech and pharmaceutical companies, and drug regulators interested in vaccinology and immunotherapy. Human Vaccines & Immunotherapeutics is affiliated with the International Society for Vaccines (ISV) and the Association for Cancer Immunotherapy (CIMT). The aim of Human Vaccines & Immunotherapeutics is to provide a platform to present and discuss developments in human vaccinology and immunotherapy. The journal covers the following topics: Research and development and new technologies for novel vaccines and immunotherapeutics Vaccines and immunotherapeutics for treating both infectious and non-infectious diseases, e.g. cancer Preclinical studies and assays Clinical trials for vaccines and immunotherapeutics Disease processes and mechanisms, including biomarkers Licensed products and their use in the field Knowledge, attitude, practices, acceptance and hesitation for vaccination and immunotherapy Interventions and policy Impact of licensed vaccines and immunotherapeutics on disease and health economics Safety and surveillance of licensed vaccines and immunotherapeutics Prevention and treatment in the developing world Epidemiology and pharmaco-economics Human Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rapid Communications, Data Notes, Article Commentaries, Meeting Reports, Plain Language Summaries of Publication and Editorials (Editors and Guest Advisors only) for publication. The journal operates a single-anonymized peer review policy. Note that bibliometric studies will only occasionally be considered and must provide a deep, rigorous analysis of current and future topics in order to bring value to the field. Bibliometric studies must be validated using the authors' own data through replication in an original sample. Pharmacological and bioinformatics studies based solely on in silico analyses without experimental validation are not considered. The Journal does not accept Traditional Chinese Medicine studies. The journal accepts replication studies, provided that the study adds significantly to the body of
From the journal's Aims & Scope
Research area (LetPub): BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY
Editor-in-chief Ronald EllisPublisher website
Editorial board by country: 22 in mainland China (about 20%); most named United States 35, Mainland China 22, Italy 8, Australia 6, United Kingdom 5 (111 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Vaccine Coverage and HesitancySocial Sciences11.1%
- Influenza Virus Research StudiesMedicine9.5%
- Bacterial Infections and VaccinesImmunology and Microbiology7.5%
- Pneumonia and Respiratory InfectionsMedicine6.8%
- Immunotherapy and Immune ResponsesImmunology and Microbiology5.6%
- Hepatitis B Virus StudiesMedicine5.3%
- SARS-CoV-2 and COVID-19 ResearchMedicine4.7%
- Viral gastroenteritis research and epidemiologyMedicine4.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Biotechnology & Applied Microbiology | Zone 3 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Biotechnology & Applied Microbiology | Zone 2 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Biotechnology & Applied Microbiology | Zone 3 |
| Minor | Immunology | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q2 · best quartile · 2025
- CiteScore Q1 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIELetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceScopusMEDLINEPubMedEmbaseDOAJPublisher website
Other: Adis International Ltd. - Reactions Weekly (Online), EBSCOhost - Biological Abstracts (Online), Thomson Reuters - Biological Abstracts (Online)
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.13LetPub ·
- Impact factor (publisher) 2025
- 4.2Publisher website ·
- 5-year impact factor (publisher) 2025
- 3.7Publisher website ·
- CiteScore (publisher) 2025
- 7.4Publisher website ·
- SJR (publisher) 2025
- 1.09Publisher website ·
- SNIP (publisher) 2025
- 1.08Publisher website ·
- h-index
- 74OpenAlex ·
- i10-index
- 492OpenAlex ·
- 2-year mean citedness
- 0OpenAlex ·
- Self-citation rate
- 9.5%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 514LetPub ·
- Downloads per year (publisher)
- 3,600,000Publisher website ·
- Downloads per year (publisher) 2025
- 3,600,000Publisher website ·
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
95 daysMedian, submission to acceptance · P25–P75 75 days – 124 days
- Acceptance to online
- median 15 days (100 articles)
- Submission to online
- median 119 days
- Sample
- 100 articles with submission and acceptance dates (1,105 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 2 monthsLetPub ·
- Average acceptance (community reports)
- 50%LetPub ·
- Acceptance rate (publisher)
- 50%Publisher website ·
- Acceptance rate (publisher) 2025
- 50%Publisher website ·
- Submission to first decision
- 27 daysPublisher website ·
- Submission to first decision 2025
- 27 daysPublisher website ·
- First decision after review
- 49 daysPublisher website ·
- First decision after review 2025
- 49 daysPublisher website ·
- Acceptance to publication
- 16 daysPublisher website ·
- Acceptance to publication 2025
- 16 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare1 items from the author guidelines
- Not considered
- Traditional Chinese Medicine studies
Article types accepted21
- article commentariesHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- article commentaryHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- case reportHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- case reportsHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- data noteHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- data notesHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- editorialHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- editorialsHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- meeting reportHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- meeting reportsHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- methodsHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- plain language summaries of publicationHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- plain language summary of publicationHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- product reviewHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- product reviewsHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- rapid communicationHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- rapid communicationsHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- research articleHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- research articlesHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- review articleHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
- review articlesHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…Length not stated
Policy excerpts from the journal's websiteData availability, Open access, Peer review
- Data availability
Share Upon Reasonable Request Model summary
The journal also now has a Share Upon Reasonable Request data sharing policy.
Source ↗Publisher website ·- Open access Open access
Human Vaccines & Immunotherapeutics is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the discoverability and readership of your article Make an impact and reach new readers, no…
Source ↗Publisher website ·- Peer review
Single-anonymized peer review Model summary
The journal operates a single-anonymized peer review policy.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- TAYLOR & FRANCIS INC
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 2005
- ISSN
- 1554-8600
- Print ISSN
- 2164-5515
- Electronic ISSN
- 2164-554X
- Latest issue on the website
- Volume 22, Issue 1 (2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Human Vaccines & Immunotherapeutics
What CAS zone is Human Vaccines & Immunotherapeutics in?
In the 2025 upgraded edition of the CAS Journal Ranking, Human Vaccines & Immunotherapeutics is in Zone 3 of Medicine, and in Zone 3 of the minor category Biotechnology & Applied Microbiology / Immunology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Human Vaccines & Immunotherapeutics?
The latest impact factor listed by LetPub is 4.13; h-index 74.
How long does peer review take at Human Vaccines & Immunotherapeutics?
Based on the dates recorded on 100 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 95 days (interquartile range 75–124 days); authors report an average review time of about 2 months; the community-reported acceptance is “about 50%”; the journal's website gives an acceptance rate of 50% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Human Vaccines & Immunotherapeutics in?
The journal's website gives JCR Q2 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 3 of Medicine.
Where are the editorial board members of Human Vaccines & Immunotherapeutics based?
Of the 111 board members whose country the journal's board page names, 22 (about 20%) are in mainland China; the countries named most often are United States (35), Mainland China (22) and Italy (8). Counted from the institutions listed on the board page; for reference only.
Which databases index Human Vaccines & Immunotherapeutics?
According to LetPub and DOAJ records, Human Vaccines & Immunotherapeutics is indexed in SCIE. The journal's website also lists Web of Science, Scopus, MEDLINE, PubMed, Embase and DOAJ; that list has not been checked against each database.
Is Human Vaccines & Immunotherapeutics open access, and what is the APC?
Human Vaccines & Immunotherapeutics is a subscription journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .